Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.

Study Overview

• Status: Completed
• Conditions: Depression
• Intervention / Treatment: Drug: Placebo; Drug: Armodafinil

• Study Type: Interventional
• Enrollment (Actual): 492
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina
    • B.A. Psychiatric Research Cent
  • Buenos Aires, Argentina
    • Dr. Gregorio Hugo Sorin
  • Buenos Aires, Argentina
    • INECO
  • Buenos Aires, Argentina
    • Instituto Fleni
  • Córdoba, Argentina
    • Sanatorio Prof. León S. Morra SA
  • Rosario, Argentina
    • Centro de Investigación y Asistencia en Psiquiatría (CIAP)
• Australia
  • Victoria
    • Malvern, Victoria, Australia
      • Neurotherapy Victoria Clinical Trials
    • Melbourne, Victoria, Australia
      • Northern Area Mental Health Services Northern Psychiatric R
• Bulgaria
  • Bourgas, Bulgaria
    • District Department of Psychiatric Disorders With Stationary
  • Pazardjik, Bulgaria
    • State Psychiatric Hospital - Pazardjik
  • Pleven, Bulgaria
    • Psychiatric clinic for women UMHAT "Dr. Georgi Stranski"
  • Plovdiv, Bulgaria
    • ODPZS- EOOD, Plovdiv, Bulgaria
  • Sofia, Bulgaria
    • MHAT Doverie
  • Sofia, Bulgaria
    • Psychiatric clinic, University Hospital "Alexandrovska"
  • Varna, Bulgaria
    • Diagnostic Consultative Center "Tchaika"
  • Varna, Bulgaria
    • MHAT - Sveta Marina
• Canada
  • Alberta
    • Edmonton, Alberta, Canada
      • Grey Nuns Hospital
  • British Columbia
    • Penticton, British Columbia, Canada
      • Dr. Alexander McIntyre, Inc.
  • Ontario
    • Kingston, Ontario, Canada
      • Providence Care Mental Health Services
    • Mississauga, Ontario, Canada
      • Medical Research Associates
  • Quebec
    • Montreal, Quebec, Canada
      • Hôpital Louis Hlafontaine
• France
  • Dole, France
    • CMP/CHS du Jura
  • Jonzac, France
    • Centre Hospitalier de Jonzac
  • Nîmes, France
    • Hopital Universitaire Caremeau-Batiment Polyvalent, Service
• Poland
  • Bydgoszcz, Poland
    • Szpital Uniwersytecki im.dr.A.Jurasza w Bydgoszczy
  • Gdansk, Poland
    • Klinika Chorob Psychicznych i Zaburzen Nerwicowych GUM
  • Gdansk, Poland
    • Wojewodzki Szpital Psychiatryczny im. prof. Tadeusza Bilikie
  • Krakow, Poland
    • Malopolskie Centrum Medyczne
• South Africa
  • Cape Town, South Africa
    • Flexivest Fourteen Research Centre
  • Cape Town, South Africa
    • Cape Trial Centre
  • Cape Town, South Africa
    • Knighton Surgery
  • Centurion, South Africa
    • Vista Clinic
  • Johannesburg, South Africa
    • Dr Magnus & Dr Brink
  • Paarl, South Africa
    • Paarl Medical Centre
  • Pretoria, South Africa
    • Dey Clinic
• Spain
  • Coslada (Madrid), Spain
    • Hospital del Henares
  • Pamplona, Spain
    • Clinica Universitaria De Navarra
  • Vitoria, Spain
    • Hospital Santiago Apostol
  • Vitoria-Gasteiz, Spain
    • Hospital Psiquiátrico de Álava
• Ukraine
  • Donetsk, Ukraine
    • Donetsk National Medical University n.a. M. Horkyy
  • Kharkiv, Ukraine
    • Public Institution "Institute of Neurology, Psychiatry and N
  • Kiev, Ukraine
    • Kiev City Psychoneurological Hospital N 1, CNTRP
  • Lviv, Ukraine
    • Danylo Galitsky Lviv State Medical University
  • Odessa, Ukraine
    • Odessa Regional Psychoneurology Dispensary
  • Vinnitsa, Ukraine
    • Vinnytsa National Medical University named by M.I. Pirogov
  • Odessa
    • s. Oleksandrivka, Odessa, Ukraine
      • Odessa Regional Mental Hospital #2
• United States
  • Alabama
    • Birmingham, Alabama, United States
      • Birmingham Psychiatry Pharmaceutical Studies, Inc
  • California
    • Anaheim, California, United States
      • South Coast Medical Associates/SC Clinical Trials, Inc.
    • Cerritos, California, United States
      • Comprehensive Neuroscience
    • Imperial, California, United States
      • Sun Valley Behavioral Medical
    • Oceanside, California, United States
      • North County Clinical Research
    • Pico Rivera, California, United States
      • CNRI Los Angeles LLC
    • San Diego, California, United States
      • CNRI-San Diego LLC
    • Santa Ana, California, United States
      • Clinical Innovations Inc.
    • Sherman Oaks, California, United States
      • Schuster Medical Research Institute
    • Stanford, California, United States
      • Stanford University Medical Center
    • Temecula, California, United States
      • Viking Clinical Research Center
  • District of Columbia
    • Washington DC, District of Columbia, United States
      • Comprehensive Neuroscience
  • Florida
    • Aventura, Florida, United States
      • Scientific Clinical Research, Inc.
    • Bradenton, Florida, United States
      • Florida Clinical Research Center
    • Jacksonville, Florida, United States
      • Clinical NeuroScience Solutions Inc
    • Lauderhill, Florida, United States
      • Fidelity Clinical Research
    • Orlando, Florida, United States
      • Compass Research, LLC
    • Tampa, Florida, United States
      • Stedman Clinical Trials, LLC
  • Georgia
    • Atlanta, Georgia, United States
      • Atlanta Center for Medical Research
    • Smyrna, Georgia, United States
      • Carman Research
  • Hawaii
    • Honolulu, Hawaii, United States
      • Hawaii Clinical Research Center
  • Illinois
    • Oakbrook Terrace, Illinois, United States
      • Midwest Center for Neurobehavioral Medicine
    • Park Ridge, Illinois, United States
      • CNS - Comprehensive Neuro Science
  • Kentucky
    • Crestview Hills, Kentucky, United States
      • Community Research
  • Massachusetts
    • Fall River, Massachusetts, United States
      • AccelRx Research
  • Minnesota
    • Rochester, Minnesota, United States
      • Mayo College of Medicine
  • Mississippi
    • Flowood, Mississippi, United States
      • Precise Research Centers
  • New Jersey
    • Mount Laurel, New Jersey, United States
      • CRI Worldwide, LLC
  • New York
    • Brooklyn, New York, United States
      • Behavioral Medical Research of Brooklyn
    • New York, New York, United States
      • Fieve Clinical Services, Inc.
    • New York, New York, United States
      • Medical and Behavioral Health Research
    • Staten Island, New York, United States
      • Richmond Behavioral Associates
    • Staten Island, New York, United States
      • Behavioral Medical Research Of Staten Island
  • Ohio
    • Beachwood, Ohio, United States
      • North Coast Clinical Trials, Inc.
    • Canton, Ohio, United States
      • Neuro-Behavioral Clinical Research, Inc
  • Oklahoma
    • Oklahoma City, Oklahoma, United States
      • IPS Research Company
  • Oregon
    • Portland, Oregon, United States
      • Oregon Center for Clinical Investigators, Inc. (OCCI, Inc.)
  • Pennsylvania
    • Allentown, Pennsylvania, United States
      • Lehigh Center for Clinical Research
    • Philadelphia, Pennsylvania, United States
      • Belmont Center For Comprehensive Treatment
  • Texas
    • Austin, Texas, United States
      • FutureSearch Trials of Neurology
    • Desoto, Texas, United States
      • InSite Clinical Research
    • Houston, Texas, United States
      • Red Oak Psychiatry Associates, P.A.
    • Irving, Texas, United States
      • University Hills Clinical Research
  • Utah
    • Orem, Utah, United States
      • Aspen Clinical Research, LLC
    • Salt Lake City, Utah, United States
      • Clinical Methods
  • Virginia
    • Richmond, Virginia, United States
      • Alliance Research Group

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The patient has a diagnosis of bipolar I disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and is currently experiencing a major depressive episode.
• Documentation that the patient has had at least 1 previous manic or mixed episode.
• The patient has had no more than 6 mood episodes in the last year.
• The patient's current major depressive episode must have started no less than 2 weeks and no more than 12 months prior to the screening visit. The current depressive episode must have begun after the patient's current mood stabilizer regime began.
• The patient must have been taking 1 (or 2) of the following protocol-allowed mood stabilizers: lithium, valproic acid, lamotrigine, aripiprazole, olanzapine, risperidone, or ziprasidone (only if taken in combination with lithium or valproic acid).
• Written informed consent is obtained.
• The patient is a man or woman 18 through 65 years of age.
• The patient is in good health (except for diagnosis of bipolar I disorder) as judged by the investigator, on the basis of medical and psychiatric history, medical examination, electrocardiography (ECG), serum chemistry, hematology, and urinalysis.
• Women of childbearing potential (women who have not reached menopause, women who are less than 2 years postmenopausal, and women who are not surgically sterile) who are sexually active must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
• The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.
• The patient has permanent accommodations and means of being contacted by the study center.
• The patient understands that they may enroll in this clinical study only once and may not enroll in any other clinical study while participating in this trial.

Exclusion Criteria:

• The patient has any Axis I disorder apart from bipolar I disorder that was the primary focus of treatment within 6 months of the screening visit or during the screening period.
• The patient has psychotic symptoms or has had psychosis within 4 weeks of the screening visit or during the screening period.
• The patient has current active suicidal ideation, is at imminent risk of self-harm, or has a history of significant suicidal ideation or suicide attempt at any time in the past that causes concern at present.
• The patient has a history of an eating disorder or obsessive compulsive disorder (OCD) within 6 months of the screening visit or during the screening period.
• The patient has a history of alcohol or substance abuse or dependence (with the exception of nicotine dependence) within 3 months of the screening visit or during the screening period.
• The patient has a history of any cutaneous drug reaction or drug hypersensitivity reaction, a history of any clinically significant hypersensitivity reaction, or a history of multiple clinically relevant allergies.
• The patient has any clinically significant uncontrolled medical condition, treated or untreated.
• The patient has received modafinil or armodafinil within the past 5 years, or the patient has a known sensitivity to any ingredients in the study drug tablets.
• The patient has previously participated in a clinical study with armodafinil or has used any investigational product within 90 days of screening. The patient may not enroll in any other clinical study while participating in this study.
• The patient has ever been treated with vagus nerve stimulation (VNS) or deep brain stimulation (DBS), or has been treated with electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) within 3 months of the screening visit.
• The patient is a pregnant or lactating woman.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.	Drug: Placebo; Matching Placebo, also in tablet form taken orally, once daily in the morning.
Experimental: Armodafinil 150 mg/day; Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.	Drug: Armodafinil; Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.; Other Names: Nuvigil; CEP-10953
Experimental: Armodafinil 200 mg/day; Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.	Drug: Armodafinil; Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.; Other Names: Nuvigil; CEP-10953

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)	The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits. Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Responders At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score	A responder is a participant with a ≥50% decrease or greater from baseline in the total score of the IDS-C30. The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits. Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Percentage of Participants in Remission At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score	A participant in remission was defined as a participant with an IDS-C30 total score of 11 or less. The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits. Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression.	Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Change From Baseline to Different Treatment Weeks in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)	The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits. Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Change From Baseline to Different Treatment Weeks in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)	The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Change From Baseline to Different Treatment Weeks in the Clinical Global Impression of Severity (CGI-S) for Depression	The CGI-S is an observer-rated scale that measures illness severity on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Participants With Treatment-Emergent Adverse Events (TEAE)	AEs were graded by the investigator for severity on a three-point scale: mild, moderate and severe. Causality is graded as either related or not related. A serious adverse event (SAE) is an AE resulting in death, a life-threatening adverse event, hospitalization, a persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may require medical intervention to prevent any of the previous results. Protocol-defined adverse events requiring expedited reporting included skin rash, hypersensitivity reaction, emergent suicidal ideation or suicide attempt, and psychosis.	Day 1 to Week 9
Change From Baseline to Weeks 4, 8 and Endpoint in the Global Assessment for Functioning (GAF) Scale	The Global Assessment of Functioning (GAF) is a numeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults, e.g., how well or adaptively one is meeting various problems-in-living. Ratings of 1 - 10 mean the participant is in persistent danger of severely hurting self or others (e.g., recurrent violence) or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death. Ratings of 91 - 100 indicate no symptoms, and the participant exhibits superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. Positive change from baseline values indicate improvement in functioning.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Change From Baseline to Endpoint in the Young Mania Rating Scale Total Score	The YMRS is a clinician-rated, 11-item checklist used to measure the severity of manic episodes. Information for assigning scores is gained from the participant's subjective reported symptoms over the previous 48 hours and from clinical observation during the interview. Seven items are ranked 0 through 4 and have descriptors associated with each severity level. Four items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 through 8 and have descriptors for every second increment. The total scale is 0-60. A score of ≤12 indicates remission of manic symptoms, and higher scores indicate greater severity of mania. Negative change from baseline scores indicate a decrease in severity of mania.	Day 0 (baseline), Week 8 or last postbaseline observation (up to 8 weeks)
Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score	HAM-A measures the severity of anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Negative change from baseline scores indicate a decrease in severity of anxiety.	Day 0 (baseline), Week 8 or last postbaseline observation (up to 8 weeks)
Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score	The ISI is a participant-rated, 7-item questionnaire designed to assess the severity of the participant's insomnia. Each item is ranked 0 (none) through 4 (very severe) and has a descriptor associated with each severity level. Total range is 0 (no insomnia) to 28 (very severe insomnia). Responses to each item are added to obtain a total score to determine the severity of insomnia. Negative change from baseline scores indicate a decrease in severity of insomnia.	Day 0 (baseline), Week 8 or last postbaseline observation (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Actual Attempt Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Actual Attempt question records whether the participant committed a potentially self-injurious act with at least some wish to die since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Non-Suicidal Self-Injurious Behavior Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Non-Suicidal Self-Injurious Behavior question records whether the participant committed a potentially self-injurious act that was not associated with a wish to die since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Interrupted Attempt Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Interrupted Attempt question records whether the participant was interrupted by an outside circumstance from starting the potentially self-injurious act with at least some wish to die since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Aborted Attempt Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Aborted Attempt question records whether the participant began to take steps toward making a suicide attempt but stops themselves before starting the potentially self-injurious act since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Suicidal Behavior Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Suicidal Behavior question records whether in the clinician's opinion, the participant exhibited suicidal behavior since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Preparatory Acts or Behavior Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Preparatory Acts or Behavior question records whether the participant exhibited acts or preparations towards imminently making a suicide attempt since the last visit. .	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Completed Suicide Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Completed Suicide question records whether the participant intentionally causing his/her's own death since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Wish to Be Dead Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Ideation - Wish to Be Dead question records whether the participant endorses thoughts about a wish to dead or not alive anymore, or a wish to fall asleep and not wake up since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Non-Specific Active Suicidal Thoughts Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Ideation - Non-Specific Active Suicidal Thoughts question records whether the participant shares general non-specific thoughts of wanting to end one's life/commit suicide since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act question records whether the participant endorses thoughts of suicide and has thought of at least one method but has no specific plan of action since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Some Intent to Act Without a Specific Plan Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Ideation - Some Intent to Act Without a Specific Plan question records whether the participant has active suicidal thoughts of killing oneself and reports having some intent to act on such thoughts since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Specific Plan and Intent Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Ideation - Specific Plan and Intent question records whether the participant has active suicidal thoughts of killing oneself with details of plan fully or partially worked out and the participant has some intent to carry out the plan since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

Collaborators and Investigators

• Sponsor: Cephalon

Publications and helpful links

General Publications

• Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015 Aug 1;181:87-91. doi: 10.1016/j.jad.2015.04.012. Epub 2015 Apr 15.

Study record dates

Study Major Dates

• Study Start: March 1, 2010
• Primary Completion (Actual): November 1, 2012
• Study Completion (Actual): November 1, 2012

Study Registration Dates

• First Submitted: February 19, 2010
• First Submitted That Met QC Criteria: February 19, 2010
• First Posted (Estimate): February 22, 2010

Study Record Updates

• Last Update Posted (Estimate): April 27, 2016
• Last Update Submitted That Met QC Criteria: April 26, 2016
• Last Verified: April 1, 2016

More Information

Terms related to this study

• Keywords: Bipolar I Disorder
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; Central Nervous System Stimulants; Wakefulness-Promoting Agents; Modafinil
• Other Study ID Numbers: C10953/3072; 2009-016634-27 (EudraCT Number)